How much does Airuini (Pyrotinib Maleate Tablets) Cost& price without insurance in China?
Airuini® is the domestic commercial brand name of Pyrotinib Maleate Tablets, an oral irreversible pan-HER tyrosine kinase inhibitor independently developed by Jiangsu Hengrui Pharmaceuticals. It inhibits EGFR, HER2 and HER4 simultaneously, blocks downstream oncogenic signaling pathways, and suppresses proliferation of HER2-positive breast cancer cells.
Main Indications
Combined with capecitabine for HER2-positive recurrent or metastatic breast cancer patients previously treated with anthracycline or taxane chemotherapy.
Combined with trastuzumab plus docetaxel for first-line treatment of HER2-positive recurrent or metastatic breast cancer without prior anti-HER2 therapy.
Combined with trastuzumab plus docetaxel for neoadjuvant therapy of HER2-positive early or locally advanced breast cancer.
Common Side Effects
Common mild adverse reactions: Diarrhea, nausea, vomiting, hand-foot syndrome, fatigue, decreased appetite and stomatitis.
Laboratory abnormalities: Neutropenia, leukopenia, elevated liver transaminases and hypokalemia.
Severe but uncommon risks: Severe dehydrating diarrhea, grade 3/4 liver injury, severe cutaneous adverse reactions and interstitial lung disease.
Approval Status in China
Airuini® (Pyrotinib Maleate Tablets, 160mg) obtained conditional marketing approval in China in August 2018. It is a prescription targeted anti-tumor drug included in China’s Category B medical insurance catalogue.
Buy Airuini (Pyrotinib Maleate Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
